title: Anti-estrogenic agents might be more favorable option for treatment of hereditary hemorrhagic telangiectasia.
authors.forename: Jia Wei
authors.initials: JW
authors.lastname: Zheng
authors.forename: Qin
authors.initials: Q
authors.lastname: Zhou
authors.forename: Xiu Juan
authors.initials: XJ
authors.lastname: Yang
authors.forename: Yan An
authors.initials: YA
authors.lastname: Wang
authors.forename: Wei Min
authors.initials: WM
authors.lastname: Ye
authors.forename: Han Guang
authors.initials: HG
authors.lastname: Zhu
authors.forename: Zhi Yuan
authors.initials: ZY
authors.lastname: Zhang
mesh_terms: D004965:Estrogen Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D011960:Receptors, Estrogen / Q000378:metabolism; D013629:Tamoxifen; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen